Xintao Guo's research while affiliated with Tianjin First Central Hospital and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publication (1)
Background
Regorafenib (RGF) is the drug of choice for treating hepatic carcinoma (HCC), but the drug has drawbacks due to resistance and associated adverse effects. Thus, it becomes crucial to understand the causal ‘map’ of the resistance conferred by RGF, so that its clinical potency can be amplified, resulting in enhanced efficacy with reduced a...
Citations
... It is worth mentioning that mounting evidence suggests that metformin could synergize with other molecules or modalities to enhance their cytotoxic capacity. Several studies have shown that combining metformin with other drugs can increase its antitumor effects in HCC, such as sodium glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin [88], aloin [89], antifolates [90], dichloroacetate (DCA) [91], celastrol [92] and systemic hypoxia [93,94]. Zhang et al. developed a new pH-responding magnetic nanocomposite based on reduced graphene oxide that combines cisplatin and metformin to kill HepG2 and Caco-2 cells. ...
